Trial Profile
Phase II trial of LB 100 in patients with haematological malignancies
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2015
Price :
$35
*
At a glance
- Drugs LB 100 (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- Sponsors Lixte Biotechnology Holdings
- 23 Mar 2015 New trial record